Sign In   |   Register
News: Congress

EAS2018 Late Breaking Clinical Trial: EUROASPIRE V

Tuesday 8 May 2018   (0 Comments)
Posted by: Charlotta Johansson
Share |

EUROASPIRE V: Lipid control still less than optimal in Europe

EUROASPIRE is a survey of secondary preventive care in patients one year after hospitalization for an acute coronary event or hospitalization for revascularization. The latest results of this survey, EUROASPIRE V, represent an audit of the implementation of the 2016 Joint European Society of Cardiology/EAS lipid guidelines. The results were presented by Professor Guy De Backer, University of Ghent, Belgium.

Briefly, EUROASPIRE included findings from 8,261 secondary prevention patients (mean age 64 years, 26% female) who were enrolled by 131 centres across 27 countries. The findings suggest that there remains much to do to improve the implementation of guideline-recommended lipid management across Europe. While the majority of patients (84%) were receiving lipid lowering therapy (the majority statins), only about one in three of these patients (32%) attained the recommended LDL cholesterol goal of <1.8 mmol/L (<70 mg/dl); similarly, poor lipid goal attainment was reported for non-HDL cholesterol (32%). This poor goal attainment is likely to be due to poor uptake of high-intensity statin therapy; less than half (43%) of patients were maintained on high-intensity statin therapy after discharge from hospital.

The findings from EUROASPIRE V highlight the need for renewed efforts for implementation of guidelines to improve lipid management in very high-risk patients in the secondary prevention setting in Europe.

Professor De Backer discusses the implications of the EUROASPIRE V data in this video >>


Membership Software Powered by YourMembership  ::  Legal